PubMed Health⌕ Search

Biomedical subjects

Y Masuko

Publications and source records attributed to Y Masuko.

At least 19 recordsLinked to original sources
PubMed1998

A case of resection under the IVC-atrial venovenous bypass of a hepatoblastoma after intraarterial chemotherapy.

An 11-month-old infant with a huge hepatoblastoma occupying almost the entire liver was admitted to the hospital. Serum alpha fetoprotein (AFP) level was elevated to 685,120 ng/mL. Combination chemotherapy with continuous arterial infusion of tetrahydropyranyl Adriamycin (THP-Adriamycin) and cisplatin based on the 91B1 protocol of the Japanese Study Group For Pediatric Liver Tumor (JPLT) was administered as the adjuvant chemotherapy. The tumor responded to three courses of chemotherapy and shrank in size, although venocavography showed that the inferior vena cava (IVC) was completely occluded below the entry of the hepatic veins. Right hepatic trisegmentectomy was performed with an IVC-atrial venovenous bypass that prevented massive bleeding. In this case, it was recognized that the IVC-atrial venovenous bypass was advantageous in an infant. The procedure is very simple and the blood flow obtained by the bypass was sufficient. Two weeks postoperatively, three courses of chemotherapy were initiated after the protocol. The patient remains well without signs of recurrence 39 months postoperatively, and the AFP value has remained within 10 ng/mL.

Antibiotics, Antineoplastic↗
PubMed1998

[Role of the visiting nurse in pain control for the terminal cancer patient at home].

Among users of our visiting nurse station in 1997, 53 (58%) were cancer patients, and among these, 35 (66%) required pain control. Because home patients, family, and health care personnel are physically separated, nurses must provide reports and adjustments to physicians that assess pain holistically on the basis of estimated patient status and condition. Nurses also play a central role in providing necessary information to the patient and family, providing drug administration guidance and other response when pain occurs, and performing reassessment. To provide an understanding of the role nurses play in pain control in the home, the current research describes how nurses assess and respond to pain among cancer patients requiring pain control by analyzing the nursing records of 9 terminal cancer patients residing at home for a period of 1 month or more. The results indicate that nurses form pain estimates by observing pain-related indicators during visits and by assessing such factors as the cause of pain, the effect of analgesics, and effects on daily life. Based on these estimates, nurses provide care independently, make adjustments with physicians, and devise plans to counter subsequent pain. These facts suggest that estimations based on appropriate nurse assessments are crucial in "at home" conditions.

Adult↗
PubMed1998

[Support for and problems associated with the highly health care-dependent, single-living elderly].

As a result of trends toward nuclear families and fewer children, the proportion of elderly persons living alone has been increasing in recent years. While an expansion of regional welfare has been proposed, health care problems will intensify and complexity will increase wherever single-living elderly persons desiring treatment at home are highly health care-dependent. Our visiting nurse station is no exception, necessitating a careful consideration of support system preparation, as well as means to respond on an individual basis now and in the future. With the object of investigating a support system able to undertake appropriate health care at home for single-living elderly persons requiring some form of treatment, this study utilized case records at our visiting nurse station to study living conditions and support activities relating to the one-year period of 1997 for three particularly health care-dependent individuals among single-living elderly persons. In terms of health care support, the results include a proposal for convenient treatment regimens suited to activity schedules and degrees of dementia, adjustment of the number of visits based on patient status, efforts to cooperate with helpers and family and to share information, and emergency response preparation. Topics for future study include assessment methods for dementia and living capacity, and safety enhancement.

Aged↗
PubMed1997

Hemangiopericytoma of the sigmoid mesentery: report of a case with immunohistochemical findings.

Hemangiopericytoma has been described in various sites in the body but only rarely in the mesocolon. This report describes the clinical course of an 83-year-old man whose mesosigmoidal tumor (hemangiopericytoma) was resected on 11 November 1994. Immunostaining was done with the following primary antibodies: alpha-actin, vimentin, factor VIII-related antigen, chromogranin, and S-100. Staining for factor VIII-related antigen was strongly positive in the endothelial cells of the capillaries, but negative in the tumor cells. The tumor cells contained immunoreactive vimentin, but demonstrated no alpha-actin, chromogranin, or S-100. Since the operation, the patient has been disease-free for 11 months.

Actins↗
PubMed1997

Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats.

This study was designed to assess a local drug delivery system of an anticancer agent, doxorubicin (DOX), using fibrin glue (Beriplast P) as a drug carrier. In vitro release of DOX from the fibrin glue was examined by a dialysis method in the presence and absence of sodium alginate. The in vitro mean dissolution times of DOX with solution, fibrin glue, and fibrin glue containing sodium alginate were 3.7 h, 8.7 h, and 81 h, respectively, indicating a sustained release of DOX from fibrin glue, especially in the presence of sodium alginate. Fibrin glue containing 6 mg of DOX and 2.5 mg of sodium alginate was applied on the surface of an AH60C tumor at the back of rats. DOX concentrations in the tumor extracellular fluid were monitored by a microdialysis method. Local application of DOX using fibrin glue containing sodium alginate to the tumor resulted in extremely higher concentrations in the tumor extracellular fluid than those in plasma (AUC ratio > 800), indicating an advantage of the site-specific delivery of DOX using fibrin glue with sodium alginate. The tumor volumes were inversely correlated with tumor extracellular fluid-to-plasma AUC ratios (r = 0.882), suggesting the relevance of tumor size in the drug efflux from tumor to blood. In conclusion, the site-specific delivery of DOX using fibrin glue with sodium alginate to the tumor was demonstrated to be advantageous with regard to the extent and duration of drug concentrations in the tumor extracellular fluid, as assessed by a microdialysis technique.

Alginates↗
PubMed1997

Rectal absorption of ozagrel from a suppository containing its commercial tablet in healthy human subjects.

A suppository containing an ozagrel tablet was prepared using Witepsol H-15 as a base, and its rectal absorption was studied in male human volunteers. In comparison, a commercially available ozagrel tablet was administered orally to all the individuals in a cross-over design. After rectal dosing, ozagrel was absorbed rapidly at a Tmax of 0.75 h, and its elimination half-life was longer than after oral dosing. The extent of absorption of ozagrel after both administration routes was similar. However, the bioavailability of the rectal suppository is 92 +/- 37% (mean +/- S.D.; n = 6) relative to the oral tablet. The tablet-containing suppository is easy to prepare, with its content being accurate and reproducible. Thus, the present study suggests that the rectal administration of an ozagrel suppository is a practical and promising alternative to oral administration, especially for patients who cannot take tablets orally. This study demonstrated for the first time the possibility of an ozagrel suppository in human subjects.

Adult↗
PubMed1996

[Efficacy of intra-arterial chemotherapy with reservoir for patients with unresectable hepatocellular carcinoma].

Long-term results of intra-arterial chemotherapy using a reservoir (IA) for patients with unresectable hepatocellular carcinoma (HCC) were investigated. Ninety-nine patients with unresectable HCC who were treated in our department during the past 7 years were enrolled in this study. Thirty-four out of the 99 patients were treated by IA with a conventional reservoir (SR group), and 21 by IA with a double-lumen reservoir (DR group) by which IA with occlusion of hepatic arterial flow would be possible. The other 44 patients were treated by transcatheter arterial embolization (TAE group). Cumulative 1-and 2-year survival rates were 54.2 and 21.7% in DR group, respectively, and 50.8 and 35.2% in TAE group, respectively. The results of these two groups were statistically equivalent, and were more favorable than those of the SR group. Cumulative patency rate of reservoirs was maintained at 93.7% after one year and at 61.8% after two years. No difference was recognized in this rate according to the type of reservoir. We concluded that IA with a double-lumen reservoir should be taken into consideration as one of the strategies for treatment of unresectable HCC. However, maintenance of catheter-patency would be necessary for satisfactory outcome.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1995

Possibility of thermosensitive magnetoliposomes as a new agent for electromagnetic induced hyperthermia.

This study examined a possibility of dextran magnetite (DM)-incorporated thermosensitive liposomes, namely thermosensitive magnetoliposomes (TMs), as a new hyperthermic agent. The temperatures of TM suspensions and cancer tumors injected with TM suspensions were efficiently elevated up to 42 degrees C by electromagnetic induced heating at a frequency of 500 kHz under both in vitro and in vivo conditions. Thus, a possibility of TMs for selective hyperthermia was demonstrated. The temperature rises obtained at various concentrations of TMs suggest that approximately 15 mg Fe/cm3 tumor volume is adequate as a therapeutic dose of TMs for efficient selective hyperthermia.

Animals↗
PubMed1994

Treatment of lymph node recurrence in patients with hepatocellular carcinoma.

The clinicopathological features and results of lymph node dissection were investigated in four patients with hepatocellular carcinoma (HCC) who developed lymph node recurrence following hepatectomy. One patient was found to have metastasis in the periportal lymph nodes at the time of a second laparotomy, while the other three developed posterior pancreaticoduodenal lymph node metastasis. All four patients had concomitant cirrhosis of the liver and were negative for hepatitis B surface antigen. No relationship between the site of the primary lesion and the location of lymph node metastasis was found. Two of the four patients are alive and in good health 4 years and 3 months, and 7 years and 3 months after their first operation, respectively. Thus, we conclude that the posterior pancreaticoduodenal lymph nodes are the most common site of lymph node recurrence of HCC, and that dissection of the affected lymph nodes offers the best chance of long-term survival.

Carcinoma, Hepatocellular↗
PubMed1993

[Adjuvant hepatic arterial chemotherapy on hepatocellular carcinoma with THP-adriamycin and carboplatin].

We studied the effect of adjuvant hepatic arterial chemotherapy with THP-adriamycin (THP) and carboplatin (CBDCA) in patients with hepatocellular carcinoma (HCC). Fifteen patients were treated by intraarterial infusion of THP 30 mg on the second and third week after hepatectomy. CBDCA 450 mg was further injected on the fourth week (group A). Intrahepatic arterial administration of the drug was carried out through the subcutaneously implanted reservoir; one to five courses of the protocol were performed (average 2 times). Transient leukocytopenia occurred in six cases, liver dysfunction in one case, duodenal ulcer in one case and occlusion of the catheter connected reservoir in three cases. Forty-two patients not treated with this protocol postoperatively were employed as historical control (group B). There were no significant differences between group A and B in operative procedures, tumor stage, clinical stage, tumor size and other histopathological findings including nuclear DNA ploidy pattern. The two-year cumulative disease-free survival rate was 78% in group A, which was significantly better than the 55% of group B (p < 0.05). It may be concluded that intrahepatic arterial chemotherapy using THP and CBDCA plays an important role to prevent recurrences of the tumor after hepatectomy in patients with HCC.

Antibiotics, Antineoplastic↗
PubMed1992

[Hyperthermia for cancer with dextran magnetite using tubular implants].

Dextran magnetite particles (Meito Sangyo Corp.) are an aqueous magnetite zol and a nanometer complex consisting of dextran chains surrounding a core of ultrafine iron oxide. The tubular implants were made with polyester tube (3 mm diameter, 20 mm length) filled with DM aqueous zol (29%w/v). The temperature of an agar phantom with implants was measured in the inductive field. Heating was effected by creating an electromagnetic field with a 7 kW generator operating at 500kHz (Yamamoto Vinyter). The temperature was elevated 3.4 degrees at a distance of 5 mm from the implant at an inductive power of 2.6 kW. An area of 20 x 20 mm was heated while changing the power, the number of implants, and their arrangement. Selective heating of cancer was considered possible by inductive heating at 500 kHz and DM implants. Since the DM aqueous zol configuration can be readily changed, treatment of various cancers is possible.

Dextrans↗
PubMed1982

Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors.

The antitumor effects of lentinan and bacterial lipopolysaccharide (LPS) were studied. Combined treatment with lentinan and LPS was very effective against Ehrlich carcinoma in ddY mice, and the syngeneic mammary carcinoma MM46 in C3H/He mice. Studies on the effective doses and times of administration showed that a single injection of lentinan plus LPS 12 days after subcutaneous inoculation of these tumors caused complete regression in 60 approximately 90% of the animals; complete regression of MM46 carcinoma was seen in 83% of the animals.

Animals↗
PubMed1982

Changes of antitumor immunity of hosts with murine mammary tumors regressed by lentinan: potentiation of antitumor delayed hypersensitivity reaction.

From 2 weeks after sc inoculation of MM46 mammary carcinoma cells into C3H/He mice, lentinan caused tumor regression, irrespective of its administration schedule (i.e., various doses and times of treatment, before and after tumor inoculation). The humoral and cellular immune responses of tumor-bearing mice with or without lentinan treatment were studied kinetically. From 2 weeks after tumor inoculation, antitumor antibodies (detected by macrophage-mediated or complement-dependent cytotoxicity assay) and LB (a serum protein) increased in tumor-bearing mice but the delayed-type hypersensitivity reaction against tumor (T-DHR) decreased. Lentinan restored and potentiated the T-DHR. The conditions under which lentinan is effective and the antitumor reactions responsible for tumor regression are discussed on the basis of these results.

Adjuvants, Immunologic↗
PubMed1981

Typing of immunomodulators in terms of their effects on the electrophoretic pattern of serum proteins and antitumor combination therapy based on this typing.

Changes of serum proteins have recently received much attention in studies of immunomodulators. In this work, changes of serum proteins, especially LB, were studied by gel electrophoresis of sera after administration of 23 immunomodulators or antitumor agents. Fourteen of the 23 compounds increased the concentration of LB in the serum of normal ddY mice when injected once ip. Six compounds caused a very rapid (day 1) increase of LB, and 8 agents caused a slow increase (day 4 approximately day 10). On the basis of the results, these compounds were classified into type I (causing a rapid increase in LB; i.e., lipopolysaccharide, dextran sulfate and poly (I)-poly(C), type II (causing a slow increase in LB; i.g., lentinan, TAK and PS-K), and type O (causing no increase in LB; e.g., levamisole and bestatin). The antitumor activities of these three types of compounds in combination with lipopolysaccharide (type I) or lentinan (type II) were studied in an Ehrlich carcinoma-ddY mouse system. The results suggested that different types of compounds frequently showed synergistic antitumor activities. Typing of immuno-modulators and the antitumor activities of combinations of these compounds are discussed.

Adjuvants, Immunologic↗
PubMed1981

Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of the murine mammary tumor.

The antitumor effect of cyclophosphamide (CY) on a syngeneic mouse mammary tumor, MM46, was found to be due to selective elimination of host lymphoid cell populations as well as a direct cytotoxic effect of CY on tumor cells. marked inhibition of tumor growth after a single ip injection of CY on day 12 lasted for more than 3 weeks, unless the host was infused iv with spleen cells from tumor-bearing mice. The tumor-enhancing activity of spleen cells from tumor-bearing mice appeared to be mainly due to Thy 1.2 positive T lymphocytes and was no longer seen after CY treatment on day 12. The extent of tumor growth inhibition achieved with CY was critically dependent on the time of drug administration. CY had no antitumor effect when given before tumor inoculation. Associated with the antitumor effect of CY, augmentation of the antitumor delayed hypersensitivity reaction, or the cellular immune response, was observed. In contrast, the titer of antitumor antibody in the blood, or the humoral immune response, decreased. Cell transfer experiments showed that suppressor T cells for antitumor delayed hypersensitivity reaction specifically induced by the tumor inoculum were eliminated after CY treatment on day 12.

Animals↗